Abstract:<div>AbstractPTEN mutations are among the most frequent genetic alterations found in human prostate cancers. Our previous works suggest that although precancerous lesions were found in Pten heterozygous mice, cancer progression and metastasis only happened when both alleles of Pten were deleted. To understand the molecular mechanisms underlying the role of PTEN in prostate cancer control, we generated two pairs of isogenic, androgen receptor (AR)–positive prostate epithelial lines from intact conditional Pten knock-out mice that are either heterozygous (PTEN-P2 and -P8) or homozygous (PTEN-CaP2 and PTEN-CaP8) for Pten deletion. Further characterization of these cells showed that loss of the second allele of Pten leads to increased anchorage-independent growth in vitro and tumorigenesis in vivo without obvious structural or numerical chromosome changes based on SKY karyotyping analysis. Despite no prior exposure to hormone ablation therapy, Pten null cells are tumorigenic in both male and female severe combined immunodeficiency mice. Furthermore, knocking down PTEN can convert the androgen-dependent Myc-CaP cell into androgen independence, suggesting that PTEN intrinsically controls androgen responsiveness, a critical step in the development of hormone refractory prostate cancer. Importantly, knocking down AR by shRNA in Pten null cells reverses androgen-independent growth in vitro and partially inhibited tumorigenesis in vivo, indicating that PTEN-controlled prostate tumorigenesis is AR dependent. These cell lines will serve as useful tools for understanding signaling pathways controlled by PTEN and elucidating the molecular mechanisms involved in hormone refractory prostate cancer formation. [Cancer Res 2007;67(13):6083–91]</div>

Genetic Background Controls Tumor Development In Pten-Deficient Mice

Data from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Effects of genetic background on tumorigenesis in p53-deficient mice

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

PTEN C-terminal Deletion Causes Genomic Instability and Tumor Development.

Abstract LB-24: C-terminal PTEN is Essential for Maintenance of Genomic Stability and Tumor Suppression

Conditional Loss of PTEN Leads to Precocious Development and Neoplasia in the Mammary Gland.

Pten Deficiency Activates Distinct Downstream Signaling Pathways in A Tissue-Specific Manner

Subtle variations in Pten dose determine cancer susceptibility

PTEN Tumor Suppressor Regulates P53 Protein Levels and Activity Through Phosphatase-Dependent and -Independent Mechanisms

Pten Modulates Cell Cycle Progression and Cell Survival by Regulating Phosphatidylinositol 3,4,5,-Trisphosphate and Akt Protein Kinase B Signaling Pathway

PTENless means more.

Data from Murine Cell Lines Derived from <i>Pten</i> Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development

Murine Cell Lines Derived From Pten Null Prostate Cancer Show The Critical Role Of Pten In Hormone Refractory Prostate Cancer Development

Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis

Polymorphic Genetic Control of Tumor Invasion in a Mouse Model of Pancreatic Neuroendocrine Carcinogenesis

Loss of Pten Causes Tumor Initiation Following Differentiation of Murine Pluripotent Stem Cells Due to Failed Repression of Nanog.

Conditional Deletion of the Pten Gene in the Mouse Prostate Induces Prostatic Intraepithelial Neoplasms at Early Ages but a Slow Progression to Prostate Tumors.